MRNA Stock Price Today (October 2026) — Moderna, Inc. Analysis & Key Metrics 2026-10-20
Moderna, Inc. (MRNA) is trading at $242.08, up 6.69% today (as of October 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $123.61 (48.9% downside).
- Volatility is high (79.68% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: steady revenue (2.10% YoY) alongside competitive pressures in the Biotechnology space.
MRNA Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Moderna, Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $92.80B
P/E Ratio
Forward P/E: N/A
Revenue Growth
Year over Year
Analyst Target
-48.9% downside from target
Key Investor Questions About MRNA
What investors need to know before buying
Based on current market data, MRNA presents a neutral technical setup with mixed signals fundamentals.
- Technicals say: Neutral (RSI 68.99)
- Fundamentals say: Mixed signals (nuanced financial profile)
MRNA's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for MRNA investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $1.29B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, MRNA stock traded between $22.28 and $243.98 and currently trades near the high end of that range. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 79.68% annualized volatility and β=2.11, the stock exhibits high sensitivity to market moves—making MRNA suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines, coverage and TickZen analysis
Market news
Dow outperforms as Wall Street rises, healthcare stocks lead gains
OpenAI acquires startup Orchestra Bio to beef up its biotech business
The Healthcare Sector Nears a New High. These Stocks Are Leading the Charge.
OpenAI acquires Orchestra Bio to boost drug development AI, Axios reports
Should Leadership Hire Require Action From Everest Medicines (SEHK:1952) Investors?
Latest TickZen Insights
All insights →No TickZen article on MRNA yet. Our newest analysis:
Explore More Analysis for MRNA
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 6, 2026 (before the open)
Frequently Asked Questions
Common investor questions about Moderna, Inc.
Moderna, Inc. (MRNA) is currently trading at $242.08. The RSI (14-day) is at 69.0, indicating neutral territory. Wall Street analysts have a consensus "hold" recommendation. The mean analyst price target of $123.61 implies 48.9% downside from current levels. Volatility is high at 79.7% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Moderna, Inc. (MRNA): The trailing P/E ratio is not available (the company may not be profitable). Price-to-Book is 8.66. Price-to-Sales is 26.29. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 18 analysts covering MRNA, the consensus price target is $123.61. This represents a 48.9% downside from the current price of $242.08. The range spans from a low target of $45.00 to a high target of $200.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "hold". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Moderna, Inc. (MRNA) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Moderna, Inc. (MRNA) investors include: 1. High volatility (79.7% annualized)—the stock can experience significant daily price swings. 2. The company is not currently profitable on a trailing basis, which creates earnings uncertainty. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Moderna, Inc.'s (MRNA) current debt and financial health profile: Total debt stands at $1.29B. The debt-to-equity ratio is 0.19x, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 2.30, indicating strong short-term liquidity. The quick ratio is 2.07. The company holds $5.14B in cash and equivalents. Free cash flow is positive at $299.25M, providing a cushion for debt servicing and shareholder returns.